

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: 16052454				
CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)				
Palabras clave utilizadas		Diabodies, monovalent, Bi-specific, binding (CD32B/Fc gamma RIIB)/(CD79B/AGM6), stable, functional heterodimeric.		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: A61K 39/395, C07K 16/28, C07K 17/14		
		CPC (Opcional): -		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/ Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI	No hay registros que puedan afectar la patentabilidad de la solicitud.	-	-	-
EPO (27/01/2017)	WO2012162068	29/11/2012	Rv. 1-9 (Pág. 9 a 12, Párr. [0026 - 0030] - Pág. 49, Párr. [0149] - Pág. 51, Párr. [0152] - Pág. 231 -233, Párr.[0565 - 0572] - Pág. 243, Párr. [0598 - 0599]).	Y
	WO2014159940	02/10/2014	-	-
	WO2015026892	26/02/2015	-	-
Patbase*	US2007004909	04/01/2007	-	A
	US2013295121	07/11/2013	-	A
	US20100174053	08/07/2010	Rv. 1 a 9 (Pág. 6, Párr.[0029] - Pág. 7, Párr. [0031] - Pág. 88, Párr. [0568 - 0569] - (Pág. 98 - 99, Párr. [0585 - 0587] - Pág. 214, Rv. 1 - Pág. 216, Rv. 9).	Y
Patent Lens	US20100174053	08/07/2010	La secuencia de aminoácidos SEQ ID NO: 252 presenta 100% de identidad y cobertura respecto a la SEQ ID NO: 12 reclamada en la solicitud.	Y
	US20100174053	08/07/2010	La secuencia de aminoácidos SEQ ID NO: 254 presenta 100% de identidad y cobertura respecto a la SEQ ID NO: 11 reclamada en la solicitud.	Y
	US20100174053	08/07/2010	La secuencia de aminoácidos SEQ ID NO: 252 presenta 100% de identidad y cobertura respecto a la SEQ ID NO: 13 reclamada en la solicitud.	Y
	US20100174053	08/07/2010	La secuencia de aminoácidos SEQ ID NO: 254 presenta 100% de identidad y cobertura respecto a la SEQ ID NO: 14 reclamada en la	Y

solicitud.

*** Categorías especiales de documentos citados:

“A” documento que define el estado general de la técnica no considerado como particularmente relevante.

“E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior.

“P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.

“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado.

“Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.

**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.

Fecha del reporte de búsqueda:

15/06/2017

Búsqueda en PatBase



Username: SIC3@patbase.com
Subaccount: Mario Forero

Menu - Search - History - Session - Folder - Order - Help - Logoff

Information Shortcuts

#	Search query	Results	Options
4	TAC=((diabod* AND (CD32B OR CD79b))) and CPC=(C07K or A61K)	42	View Browse Hits Optimise more...
3	TAC=((diabod* AND (CD32B OR CD79b)))	44	View Browse Hits Optimise more...
2	TAC=((diabod* AND (CD32B NEAR CD79b)))	2	View Browse Hits Optimise more...
1	TAC=((diabodies AND (CD32B NEAR CD79b)))	1	View Browse Hits Optimise more...

Command Reference

- Bibliographic data
- Textual data
- Update commands
- Operators
- Navigation / shortcuts

6) Family number: 33550179 (US2007004909A)

Similar • Translate • Full-text • Status • Citations

Title: [EN] COVALENT **DIABODIES** AND USES THEREOF

Abstract: Source: US2007004909A [EN] The present invention is directed to **diabody** molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The **diabody** molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the **diabody** molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the **diabody** molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.

Classifications: Classification Explorer


International (IPC): A61K A61K39/00 A61K39/39 A61K39/395 A61K47/48 A61K9/16 A61P1/00 A61P1/04 A61P1/16 A61P11/00 A61P11/06 A61P13/12 A61P15/00 A61P17/00 A61P17/02 A61P17/06 A61P17/14 A61P19/02 A61P19/08 A61P21/04 A61P25/00 A61P25/28 A61P27/02 A61P29/00 A61P31/10 A61P31/00 A61P31/04 A61P31/12 A61P31/14 A61P31/16 A61P31/18 A61P31/20 A61P31/22 A61P33/02 A61P33/06 A61P35/00 A61P35/02 A61P37/00 A61P37/02 A61P37/06 A61P37/08 A61P39/02 A61P39/06 A61P5/14 A61P5/38 A61P7/06 A61P9/08 C07H21/04 C07K C07K16/00 C07K16/08 C07K16/12 C07K16/18 C07K16/28 C07K16/30 C07K16/32 C07K16/44 C07K16/46 C07K17/02 C07K19/00 C12N1/15 C12N1/19 C12N1/21 C12N15/02 C12N15/09 C12N15/13 C12N15/63 C12N5/10 C12P21/04 C12P21/08 (Advanced/Invention); A61K39/00 A61K39/395 A61K47/48 A61K9/16 A61P35/00 C07K16/00 C12N15/09 C12N15/13 C12N15/63 C12P21/08 (Advanced/Non-invention); A61K39/00 A61K39/39 A61K39/395 A61P31/00 A61P35/00 A61P37/00 C07H21/00 C07K16/00 C07K16/18 C07K16/46 C07K19/00 C12N1/15 C12N1/19 C12N15/02 C12N15/09 C12N15/13 C12N15/63 C12N5/10 C12P21/04 C12P21/08 (Core/Invention); C12P21/08 (Core/Non-invention); A61K A61P C07K (Subclass/Invention)

International (IPC): A61K39/395 C07K16/00

CPC: C07K16/468 C07K16/2803 C07K2317/24 C07K2317/56 C07K2317/62 C07K2317/64 C07K2317/92 C07K16/2809 C07K16/32 C07K16/44 C07K2319/00 A61K2039/505 C07K2317/622 C07K2317/34 C07K2317/52 C07K2317/626 C07K2317/73 C07K16/30 C07K16/12 C07K16/08 C07K2317/53 A61K39/395 C07K16/283 C07K16/28A C07K16/28A12 C07K16/28A26 C07K16/32 C07K16/44 C07K16/46D K61K39/505 M07K316/520 M07K317/240 M07K317/560 M07K317/620 M07K317/622 M07K317/626 M07K317/640 M07K317/730 M07K317/920 M07K319/00

US: 1/1 424/133.1 424/133.100P 424/136.1 435/252.31 435/252.33 435/254.21 435/254.23 435/320.1 435/326 435/69.6 530/387.1 530/387.100S 530/387.3 530/387.300S 530/388.8 530/388.800P 530/389.7 530/389.700P 536/23.53

Family: Family Explorer



10) Family number: 50625453 (US2013295121A)

Similar • Translate • Full-text • Status • Citations

Title: [EN] COVALENT **DIABODIES** AND USES THEREOF

Abstract: Source: US2013295121A [EN] **Diabody** molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers are disclosed. The **diabody** molecules comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the **diabody** molecule may be covalently bound through non-peptide bond covalent bonds, such as disulfide bonding of cysteine residues located within each polypeptide chain. The **diabody** molecules may further comprise an Fc region, which allows antibody-like functionality to be engineered into the molecule.


Classifications: [Classification Explorer](#)

International (IPC 8-4): A61K38/16 A61K39/395 A61P35/00 A61P35/02 A61P37/02 C07K C07K14/315 C07K16/00 C07K16/18 C07K16/28 C07K16/30 C07K16/32 C07K16/46 C07K19/00 C12N15/08 C12P21/08 (Advanced/Invention); C12P21/08 (Advanced/Non-invention); C07K16/00 (Core/Invention); A61K A61P C07K (Subclass/Invention)

CPC: C07K2317/626 A61K39/39558 C07K14/315 A61K38/164 C07K16/2809 C07K16/32 C07K2317/24 C07K2317/31 C07K2317/35 C07K2317/73 C07K2317/92 C07K2319/31 C07K2319/70 C07K16/283 C07K16/2803 C07K16/2851 C07K16/44 C07K2317/52 C07K2317/64 C07K2317/94
European: C07K16/28A26 M07K317/626
US: 424/179.1 530/350

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
AU2011286024 AA	20120209	AU20110286024	20110729	
AU2011286024 BB	20140807	AU20110286024	20110729	
CA2807127 AA	20130130	CA20112807127	20110729	
CN103154025 A	20130612	CN201180047940	20110729	
CN103154025 B	20150701	CN201180047940	20110729	
EP2601216 A1	20130612	EP20110815113	20110729	
EP2601216 A4	20131225	EP20110815113	20110729	
IL224515 A0	20130324	IL20110224515	20110729	
IL224515 A1	20160731	IL20130224515	20130130	
IN1031DN2013 A	20160226	IN2013DN01031	20130202	
JP2013540696 T2	20131107	JP20130523230T	20110729	
JP5964300 B2	20160803	JP20130523230T	20110729	



17) Family number: 58500067 (US2016194396A)

Similar • Translate • Full-text • Status • Citations

Title: [EN] BI-SPECIFIC MONOVALENT Fc **DIABODIES** THAT ARE CAPABLE OF BINDING **CD32B** AND **CD79B** AND USES THEREOF

Abstract: Source: US2016194396A [EN] The present invention is directed to bi-specific monovalent **diabodies** that comprise an immunoglobulin Fc Domain ("bi-specific monovalent Fc **diabodies**") and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of **CD32B** and one binding site specific for an epitope of **CD79b** (i.e., a "CD32BxCD79b bi-specific monovalent Fc **diabody**"). The bi-specific monovalent Fc **diabodies** of the present invention are capable of simultaneous binding to **CD32B** and **CD79b**. The invention is directed to such compositions, to pharmaceutical compositions that contain such bi-specific monovalent Fc **diabodies** and to methods for their use in the treatment of inflammatory diseases or conditions, and in particular, systemic lupus erythematosus (SLE) and graft vs. host disease.

Classifications: [Classification Explorer](#)

International (IPC 8-4): A61K A61K39/00 A61K39/395 A61P17/00 A61P29/00 A61P37/00 A61P37/02 A61P37/06 A61P37/08 C07K16/00 C07K16/28 C07K16/46 (Advanced/Invention); A61K (Subclass/Invention)

CPC: C07K2317/74 C07K2319/31 A61K39/395 C07K16/468 C07K2317/73 C07K16/283 A61K2039/505 C07K16/2803 C07K2317/31 C07K2317/52 C07K2317/60 C07K2317/624 C07K2319/73
US: 424/136.1 530/387.3

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
AR097260 AA	20160302	AR2014P102956	20140806	
AU2014306105 AA	20150212	AU20140306105	20140806	
CA2920021 AA	20160129	CA20142920021	20140806	
CL2016000293 A1	20161021	CL20160000293	20160205	
CN105611943 A	20160525	CN201480045937	20140806	
CO16052454 A2	20160630	CO20160052454	20160301	
DOP2016000044 A	20160415	DO20160000044	20160205	
EA2016090325 A1	20160930	EA20160090325	20140806	
EP3030264 A1	20160615	EP20140834798	20140806	
EP3030264 A4	20170308	EP20140834798	20140806	
IL244009 A0	20160421	IL20140244009	20140806	
IN201617003922 A	20160722	IN201617003922	20160203	
JP2016527314 T2	20160908	JP20160533386T	20140806	
KR20160042004 A	20160418	KR20167005947	20140806	

